Active substance
Results for the substance varicella zoster vaccine recombinant adjuvanted
2 results
About this active substance
The varicella-zoster vaccine (recombinant, adjuvanted) is used to prevent herpes zoster (shingles) and postherpetic neuralgia in adults. It is particularly recommended for individuals aged 50 years and older, as well as adults with weakened immune systems who are at increased risk of varicella-zoster virus (VZV) reactivation.
This vaccine contains a recombinant protein of the varicella-zoster virus, combined with an adjuvant that enhances the immune response. The adjuvant helps improve the vaccine's efficacy, providing stronger and longer-lasting protection against virus reactivation.
The vaccine is administered in two doses, spaced 2 to 6 months apart, via intramuscular injection. It is well-tolerated, but mild side effects such as pain at the injection site, fatigue, fever, headache, or muscle aches may occur. Severe reactions are rare.
It is important for patients to complete the full vaccination schedule to ensure optimal protection against shingles and its associated complications.
This vaccine contains a recombinant protein of the varicella-zoster virus, combined with an adjuvant that enhances the immune response. The adjuvant helps improve the vaccine's efficacy, providing stronger and longer-lasting protection against virus reactivation.
The vaccine is administered in two doses, spaced 2 to 6 months apart, via intramuscular injection. It is well-tolerated, but mild side effects such as pain at the injection site, fatigue, fever, headache, or muscle aches may occur. Severe reactions are rare.
It is important for patients to complete the full vaccination schedule to ensure optimal protection against shingles and its associated complications.